PDCD1 and non-small cell lung carcinoma: Our analysis shows that continued anti-PD-1 immunotherapy beyond initial progression may not improve clinical benefit for patients with NSCLC, and it is a safety profile consistent with that observed in patients who discontinued ICI treatment.